Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery

NCT02547623 is registered in ClinicalTrials.gov with ICON Bioscience Inc as lead sponsor.

NCT NCT02547623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02547623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Lead sponsor
ICON Bioscience Inc
Phase
Phase 3
Overall status
Completed
Start date
November 6, 2015
Completion date
August 16, 2016
Enrollment
194 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cataract